Details of the Drug Reposition

General Information of This Drug (ID: DMN2XK6)

Drug Name
Q203   DMN2XK6
Synonyms
Telacebec; 1334719-95-7; UNII-55G92WGH3X; 55G92WGH3X; Q-203; CHEMBL3298910; SCHEMBL12295312; MMV687696; BDBM50022086; ZINC169325657; CS-6412; Imidazo(1,2-a)pyridine-3-carboxamide, 6-chloro-2-ethyl-N-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)phenyl)methyl)-; AS-35270; HY-101040; Q 203; EN300-218150; Z2235679010; 6-chloro-2-ethyl-N-[(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide; 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]-1-piperidyl]phenyl]methyl]im
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Tuberculosis DISZIV9N 1B10-1B1Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04847583) A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)